Kimmtrak five-year overall survival data reported by Immunocore

Immunocore presented five-year overall survival data for Kimmtrak at AACR 2026 showing 16% overall survival with Kimmtrak versus 8% in the control arm in a Phase 3 trial of unresectable or metastatic uveal melanoma.

Immunocore presented five-year overall survival data for Kimmtrak in an oral session at the American Association for Cancer Research (AACR) 2026 meeting. The data come from a prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma, a disease with a historically poor prognosis and a reported five-year survival under 5%. Reported results show overall survival at five years of 16% for Kimmtrak versus 8% in the control arm. Key facts: - Data were presented at AACR 2026. - The findings are from a prospective Phase 3 randomized trial in unresectable or metastatic uveal melanoma. - Five-year overall survival was reported as 16% with Kimmtrak versus 8% in the control arm. - The results represent the longest follow-up reported for any T cell engager in a solid tumor. Summary: The reported results indicate higher five-year survival with Kimmtrak compared with the trial control arm and above historical rates for this disease. Undetermined at this time.